Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) through LRP-1 targeting, announced today that complete phase 1/2 clinical data in two clinical studies of its lead oncology program, ANG1005, for the treatment of brain cancers, including glioblastoma (GBM) and brain metastases, were presented at the 2010 American Society for Clinical Oncology (ASCO) Annual Meeting, June 4-8, in Chicago, IL. These data demonstrated that by targeting the lipoprotein receptor-related protein (LRP-1), which is highly expressed on the surface of the blood-brain barrier (BBB) and upregulated on malignant cancer cells. Angiochem's novel anticancer agent, ANG1005, gained entry into the brain and penetrated tumor cells to provide increased time to disease progression, significant reductions in tumor size and reversal of neurological deficits caused by tumor intrusion.
“Angiochem's LRP-1 targeting technology platform (EPiC) has the potential to transform targeted cell-killing cancer therapies , to a new level of effectiveness for the treatment of brain cancers, by enabling penetration of the drug through the BBB and overcoming multi-drug resistance mechanisms”
"These very encouraging results observed in the ANG1005 Phase 1/2 clinical studies clearly support further development of ANG1005 in both malignant gliomas and brain metastases, two brain cancers for which patients face a dismal prognosis with few treatment options," said Jan Drappatz, MD, Center for Neuro-Oncology at Dana-Farber Cancer Institute, Department of Neurology at Brigham and Women's Hospital, and, Harvard Medical School, and ANG 1005 lead investigator for Boston-area study centers.
Spatial aging clocks reveal how T cells and neural stem cells shape brain aging